Updated follow-up (median 55.6 months) of the phase 3 RUBY RCT in dMMR/MSI-H primary advanced or recurrent endometrial cancer: dostarlimab plus carboplatin-paclitaxel gave a 66% lower risk of death vs placebo plus chemotherapy; no new safety signals.
RCT
Powell et al. Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial